AxeRx

AxeRx is a pre-clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics that target RNA-protein interactions. The company utilizes a proprietary platform to identify compounds that can disrupt the binding of specific RNA-binding proteins (RBPs) involved in disease pathways, particularly in oncology. Founded by researchers from the University of Texas at Austin, AxeRx aims to address unmet medical needs in cancer treatment by targeting previously "undruggable" RNA-protein interfaces. The company's lead research efforts are directed toward inhibiting the eIF4F complex to treat various solid tumors. AxeRx has been supported by significant funding from the Cancer Prevention and Research Institute of Texas (CPRIT). The company's approach represents a novel strategy in precision medicine by focusing on the post-transcriptional regulation of gene expression.